...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Allergy >Modulation of allergic immune responses by mucosal application of recombinant lactic acid bacteria producing the major birch pollen allergen Bet v 1.
【24h】

Modulation of allergic immune responses by mucosal application of recombinant lactic acid bacteria producing the major birch pollen allergen Bet v 1.

机译：通过粘膜应用重组乳酸菌调节过敏性免疫反应，产生主要的桦树花粉过敏原Bet v 1。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: Probiotic lactic acid bacteria (LAB) are able to modulate the host immune system and clinical trials have demonstrated that specific strains have the capacity to reduce allergic symptoms. Therefore, we aimed to evaluate the potential of recombinant LAB producing the major birch pollen allergen Bet v 1 for mucosal vaccination against birch pollen allergy. Methods: Recombinant Bet v 1-producing Lactobacillus plantarum and Lactococcus lactis strains were constructed. Their immunogenicity was compared with purified Bet v 1 by subcutaneous immunization of mice. Intranasal application of the live recombinant strains was performed to test their immunomodulatory potency in a mouse model of birch pollen allergy. Results: Bet v 1 produced by the LAB was recognized by monoclonal anti-Bet v 1 and IgE antibodies from birch pollen-allergic patients. Systemic immunization with the recombinant strains induced significantly lower IgG1/IgG2a ratios compared with purified Bet v 1. Intranasal pretreatment led to reduced allergen-specific IgE vs enhanced IgG2a levels and reduced interleukin (IL)-5 production of splenocytes in vitro, indicating a shift towards non-allergic T-helper-1 (Th1) responses. Airway inflammation, i.e. eosinophils and IL-5 in lung lavages, was reduced using either Bet v 1-producing or control strains. Allergen-specific secretory IgA responses were enhanced in lungs and intestines after pretreatment with only the Bet v 1-producing strains. Conclusions: Mucosal vaccination with live recombinant LAB, leading to a shift towards non-allergic immune responses along with enhanced allergen-specific mucosal IgA levels offers a promising approach to prevent systemic and local allergic immune responses.
机译：背景：益生菌乳酸菌（LAB）能够调节宿主的免疫系统，临床试验表明特定菌株具有减轻过敏症状的能力。因此，我们旨在评估产生主要桦树花粉变应原Bet v 1的重组LAB对粘膜疫苗接种对桦树花粉过敏的潜力。方法：构建重组Bet v 1产乳杆菌和乳酸乳球菌菌株。通过小鼠皮下免疫将它们的免疫原性与纯化的Bet v 1进行比较。进行活重组株的鼻内施用以在桦树花粉过敏的小鼠模型中测试其免疫调节效力。结果：LAB产生的Bet v 1被桦木花粉过敏患者的单克隆抗Bet v 1和IgE抗体识别。与纯化的Bet v 1相比，重组菌株的全身免疫诱导的IgG1 / IgG2a比率明显降低。鼻内预处理导致变应原特异性IgE降低，而IgG2a水平升高，脾细胞的白介素（IL）-5产生降低，表明发生了转变对非过敏性T-helper-1（Th1）的反应。使用产生Bet v 1的菌株或对照菌株，减少了气道炎症，即肺灌洗液中的嗜酸性粒细胞和IL-5。仅用产生Bet v 1的菌株进行预处理后，肺和肠中的变应原特异性分泌IgA反应增强。结论：用活的重组LAB进行粘膜疫苗接种可导致向非过敏性免疫反应的转变，以及增强的过敏原特异性粘膜IgA水平，为预防全身和局部过敏性免疫反应提供了一种有前途的方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号